Swiss drugmaker Novartis AG sued Amgen Inc on Thursday, accusing the U.S. biotec...
NEW YORK/LOS ANGELES - Swiss drugmaker Novartis AG sued Amgen Inc on Thursday, accusing the U.S. biotechnology company of trying to wrongfully back out of agreements to jointly develop and market migraine prevention drug Aimovig, and keep the profits for itself.
Aimovig, which won U.S. and European approvals last year, belongs to a new class of medicines that also includes Eli Lilly and Co’s Emgality and Teva Pharmaceutical Industries Ltd’s Ajovy. Amgen, in an emailed statement, said it is seeking to terminate the collaboration agreements with Novartis and obtain damages, but termination would not be effective until the litigation is resolved.
“The program about which Amgen has complained is being terminated,” Novartis said, and the lack of a breach means Amgen’s April 2 notice terminating the collaboration agreements should be deemed void. Alder, which is seeking U.S. approval for an intravenous migraine treatment, has an agreement through 2023 for Sandoz to manufacture the drug, called eptinezumab, according to Alder Chief Executive Robert Azelby.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novartis sues Amgen over migraine treatment AimovigSwiss drugmaker Novartis AG sued Amgen Inc on Thursday, accusing the U.S. biotec...
Read more »
2 drug giants are feuding over a highly successful new migraine drug, and court documents reveal how profitable the $10 billion market could beTwo drugmakers, Amgen and Novartis, have worked together for years on a new type of cutting-edge migraine drug, Aimovig.
Read more »
Novartis sues Amgen over migraine treatment AimovigSwiss drugmaker Novartis AG sued Amgen Inc on Thursday, accusing the U.S. biotec...
Read more »
Biogen SMA drug price, Novartis estimates for its treatment far too high - U.S. groupBiogen Inc should slash the price of its spinal muscular atrophy (SMA) drug, and...
Read more »
Novartis pays $310 million upfront for inflammation specialist IFMNovartis on Monday said it had agreed to pay $310 million (£238 million) upfront...
Read more »
Swiss drugmaker Novartis must face doctor kickback suit, U.S. judge rulesNovartis AG must face a U.S. government lawsuit accusing it of paying millions o...
Read more »
MIT cuts collaborations with Chinese tech firms Huawei, ZTEThe Massachusetts Institute of Technology (MIT) said on Wednesday it has cut col...
Read more »